dofequidar has been researched along with cytarabine in 1 studies
Studies (dofequidar) | Trials (dofequidar) | Recent Studies (post-2010) (dofequidar) | Studies (cytarabine) | Trials (cytarabine) | Recent Studies (post-2010) (cytarabine) |
---|---|---|---|---|---|
40 | 2 | 5 | 15,487 | 2,424 | 3,188 |
Protein | Taxonomy | dofequidar (IC50) | cytarabine (IC50) |
---|---|---|---|
nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 7.533 | |
E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.02 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ohno, R; Takeshita, A | 1 |
1 review(s) available for dofequidar and cytarabine
Article | Year |
---|---|
[New combination therapies in hematological malignancies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporins; Cytarabine; Doxorubicin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, B-Cell; Myelodysplastic Syndromes; Prednisone; Quinolines; Rituximab; Tretinoin; Vidarabine; Vincristine | 2000 |